Trastuzumab Deruxtecan
Angiosarcoma
QuantumLeap Healthcare Collaborativeantibody_drug_conjugatePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
49 Active assets in the Angiosarcoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Pembrolizumab Memorial Sloan Kettering Cancer Center | Phase 2 | B |
Sorafenib National Cancer Institute (NCI) | Phase 2 | B |
Trilaciclib QuantumLeap Healthcare Collaborative | Phase 2 | CCC |
Rilvegostomig QuantumLeap Healthcare Collaborative | Phase 2 | CCC |
Metformin QuantumLeap Healthcare Collaborative | Phase 2 | CCC |
View all 50 →
Same molecule, other indications
Trastuzumab Deruxtecan is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →